title: Clinical outcomes in children with Henoch-Schönlein purpura nephritis without crescents.
abstract: BACKGROUND
  Henoch-Schönlein purpura is the most common vasculitis in children. Its long-term prognosis depends on renal involvement. The management of Henoch-Schönlein purpura nephritis (HSPN) remains controversial. This study reports the prognosis of children with HSPN presenting with class 2 International Study of Kidney Disease in Children (ISKDC) nephritis.
  
  
  METHODS
  All children with HSPN class 2 diagnosed between 1995 and 2015 in four pediatric nephrology centers were included, and clinical and biological data were collected from the medical files. The primary endpoint was proteinuria remission defined as a proteinuria <200 mg/L.
  
  
  RESULTS
  Ninety-two children were included in the study with a median follow-up of 36 (6-120) months; 28% had nephrotic syndrome, 31% proteinuria >3 g/L, 52% proteinuria between 1 and 3 g/L, and 18% proteinuria <1 g/L. Forty-seven percent of patients received orally treatment with steroids alone, 37% received methylprednisolone pulses followed by steroids orally, 18% received no steroids. Although 85% reached remission during follow-up, 12% did not maintain complete remission over time so that only 75% remained in complete remission by the end of the follow-up. Univariate analysis found a higher likelihood of remission in patients with higher proteinuria at disease onset (p = 0.009). This trend was not found in the multivariate analysis after adjusting for treatments, as patients with higher proteinuria were most often treated with steroids.
  
  
  CONCLUSIONS
  Our study shows that one fourth of patients with HSPN class 2 remain proteinuric and thus carry the risk of developing chronic kidney disease over the long term. This finding, together with the better outcome of patients treated with steroids, is in favor of using high-dose steroids orally or IV in these patients.
authors.affiliation: Pediatric Nephrology, Armand Trousseau Hospital, APHP, 26 Avenue du Docteur Netter, Paris, 75012, France.|University Pierre and Marie Curie, Paris 6, Paris, France.
authors.forename: Jean Daniel
authors.initials: JD
authors.lastname: Delbet
authors.affiliation: Pediatric Nephrology, Robert Debré Hospital, APHP, Paris, France.|University Paris Diderot, Paris 7, Paris, France.
authors.forename: Julien
authors.initials: J
authors.lastname: Hogan
authors.affiliation: Pediatric Nephrology, Armand Trousseau Hospital, APHP, 26 Avenue du Docteur Netter, Paris, 75012, France.
authors.forename: Bilal
authors.initials: B
authors.lastname: Aoun
authors.affiliation: Pediatric Nephrology, Armand Trousseau Hospital, APHP, 26 Avenue du Docteur Netter, Paris, 75012, France.|University Pierre and Marie Curie, Paris 6, Paris, France.
authors.forename: Iulia
authors.initials: I
authors.lastname: Stoica
authors.affiliation: Pediatric Nephrology, Necker Enfants Malades, APHP, Paris, France.
authors.forename: Rémi
authors.initials: R
authors.lastname: Salomon
authors.affiliation: Pediatric Nephrology and Rheumatology, CHU Toulouse, Paris, France.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Decramer
authors.affiliation: University Pierre and Marie Curie, Paris 6, Paris, France.|Pathology Department, Tenon Hospital, APHP, Paris, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Brocheriou
authors.affiliation: Pediatric Nephrology, Robert Debré Hospital, APHP, Paris, France.|University Paris Diderot, Paris 7, Paris, France.
authors.forename: Georges
authors.initials: G
authors.lastname: Deschênes
authors.affiliation: Pediatric Nephrology, Armand Trousseau Hospital, APHP, 26 Avenue du Docteur Netter, Paris, 75012, France. tim.ulinski@trs.aphp.fr.|University Pierre and Marie Curie, Paris 6, Paris, France. tim.ulinski@trs.aphp.fr.|DHU i2b, Inflammation-Immunopathology-Biotherapy, Paris, France. tim.ulinski@trs.aphp.fr.
authors.forename: Tim
authors.initials: T
authors.lastname: Ulinski
mesh_terms: D001706:Biopsy; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D011695:IgA Vasculitis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000652:urine; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007668:Kidney / Q000473:pathology; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D009393:Nephritis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000652:urine; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000652:urine; D011379:Prognosis; D011507:Proteinuria / Q000188:drug therapy* / Q000473:pathology / Q000652:urine; D012074:Remission Induction / Q000379:methods; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D008775:Methylprednisolone
keywords: Crescents; Henoch–Schönlein purpura nephritis; ISKDC classification; Pediatric; Prognosis; Renal outcomes